NCT05136599View on ClinicalTrials.gov

Establishing a Controlled Human Infection Model of Bordetella Pertussis

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Pertussis
Interventions
BIOLOGICAL

Bordetella pertussis D420

Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.

Trial Locations (1)

B3K 6R8

Canadian Center for Vaccinology, Halifax

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Centers for Disease Control and Prevention

FED

collaborator

Vanderbilt University Medical Center

OTHER

lead

Dalhousie University

OTHER